In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

European Chemicals Agency's list of "substances of very high concern" (SVHCs) is likely to have profound effect on chemical production and use in the U.S., according to Sept. 30 report issued by Environmental Defense Fund. Chemicals deemed SVHCs are those identified by REACH as carcinogenic, mutagenic, reproductive toxins, bioaccumulative or otherwise injurious to human health. Use of SVHCs will have to be authorized by ECHA; a first draft of the SVHC list is likely to be released in late October. While ECHA's proposed SVHC list currently has 16 chemicals, Environmental Defense Fund says pressure from advocacy organizations could balloon list to nearly 300 chemicals, many of which are in active commerce in the U.S. - a move that would have "a major impact on chemical production" in this country. Some of the 300 chemicals are used in personal care or in personal-care packaging, such as formaldehyde and bisphenol A. The Environmental Defense Fund report, plus a list of the chemicals, is available at

You may also be interested in...

Pipeline Watch: First Approvals For Vadadustat, Daprodustat, In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Coronavirus Update: Japan's Supercomputer Joins COVID-19 Drug Hunt

Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, and understanding infection spread simulations and socio-economic impact.

MiMedx Raises $150M To Scale Advanced Wound Care Product Biz

Wound care company MiMedx has raised $150m in private equity and debt financing from EW Healthcare Partners and Hayfin Capital Management. The funds will be used to scale commercialization of the company’s amniotic tissue products.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts